Trial Profile
Prospective study of safety and efficacy of combination therapy using intravitreal triamcinolone acetonide and ranibizumab versus ranibizumab monotherapy for neovascular age-related macular degeneration
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Triamcinolone (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 07 Jul 2016 New trial record